CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
On Wednesday, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above.
週三，美國疾病控制與預防中心的免疫實踐諮詢委員會（ACIP）投票推薦所有75歲及以上的成年人定期使用呼吸道合胞病毒（RSV）疫苗。
The panel also recommended RSV immunization for adults aged 60-74 years who are at increased risk for severe RSV disease, meaning they have certain chronic medical conditions.
該小組還建議，具有某些慢性疾病的60-74歲成年人在面臨嚴重RSV疾病的增加風險時接種RSV免疫。
The recommendation is for adults who did not get an RSV vaccine last year. The RSV vaccine is not currently an annual vaccine.
建議針對去年未接種RSV疫苗的成年人。RSV疫苗目前不是年度疫苗。
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until additional data become available.
ACIP推遲了針對50-59歲年齡段增加RSV-LRTD風險的成年人的推薦投票，直到獲得更多數據。
GSK Plc (NYSE:GSK) says it continues to generate data.
GSK公司（紐交所：GSK）表示，仍在生成數據。
The updated recommendation for people 60 and older replaces last year's recommendation to simplify RSV vaccine decision-making for clinicians and the public.
針對60歲及以上的更新建議取代了去年的建議，以簡化臨床醫生和公衆的RSV疫苗決策。
Earlier this month, the FDA expanded the approval of GSK's Arexvy for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years at increased risk, becoming the first and only vaccine FDA-approved for adults aged 50-59 who are at increased risk for RSV-LRTD.
本月早些時候，FDA擴大了GSK的Arexvy的批准範圍，用於預防50-59歲增加風險的RSV下呼吸道疾病（LRTD），成爲首個且唯一獲得FDA批准的適用於年齡在50-59歲、面臨RSV-LRTD風險的成年人的疫苗。
In the U.S., the vaccine was approved for use in adults aged 60 and older.
在美國，該疫苗獲得了60歲及以上成年人的批准。
In April, Pfizer Inc (NYSE:PFE) released top-line immunogenicity and safety data from Phase 3 MONeT trial, evaluating a single dose of Abrysvo versus placebo in adults 18 to 59 years of age at risk of developing severe RSV-LRTD.
4月，輝瑞公司（紐交所：PFE）發佈了從18至59歲處於嚴重RSV-LRTD風險的成人中的MONeT試驗的頂線免疫原性和安全性數據。
Citing JP Morgan analyst, Reuters highlights, "We believe consensus Arexvy forecasts may now be lowered to reflect a smaller eligible U.S. patient population, confirmed Moderna Inc (NASDAQ:MRNA) competition, and more risk around GSK's two-year revaccination interval."
引用JP摩根的分析師，路透社指出：“我們認爲，Arexvy預測共識現在可能降低，以反映規模較小的美國患者人口，現已確認的Moderna公司（納斯達克：MRNA）競爭，以及GSK的兩年再接種間隔存在更多風險。”
The report also added, "The decision is a negative for GSK, which makes the Arexvy RSV vaccine."
報告還補充道：“該決定對於製造Arexvy RSV疫苗的GSK來說是負面的。”
Also Read: Why Is Moderna Stock Trading Lower On Wednesday?
還閱讀：爲什麼Moderna股票週三交易下跌？
Price Action: GSK shares are down 1.80% at $38.15 during the premarket session at the last check on Thursday.
價格行動：按照上次週四盤前會話最後一次檢查，GSK股票下跌了1.80%，至38.15美元。
Photo by JHVEPhoto on Shutterstock
照片由Shutterstock的JHVEPhoto拍攝
譯文內容由第三人軟體翻譯。